These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 18095746)

  • 1. Orlistat-associated adverse effects and drug interactions: a critical review.
    Filippatos TD; Derdemezis CS; Gazi IF; Nakou ES; Mikhailidis DP; Elisaf MS
    Drug Saf; 2008; 31(1):53-65. PubMed ID: 18095746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orlistat in the treatment of obesity.
    Ballinger A
    Expert Opin Pharmacother; 2000 May; 1(4):841-7. PubMed ID: 11249520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-the-counter orlistat. A weight loss "Alli" or adversary on the horizon.
    Anderson T
    AWHONN Lifelines; 2006; 10(5):418-21. PubMed ID: 17069574
    [No Abstract]   [Full Text] [Related]  

  • 5. Pragmatic study of orlistat 60 mg on abdominal obesity.
    Thomas EL; Makwana A; Newbould R; Rao AW; Gambarota G; Frost G; Delafont B; Mishra RG; Matthews PM; Berk ES; Schwartz SM; Bell JD; Beaver JD
    Eur J Clin Nutr; 2011 Nov; 65(11):1256-62. PubMed ID: 21697820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents.
    Zhi J; Moore R; Kanitra L
    J Am Coll Nutr; 2003 Oct; 22(5):357-62. PubMed ID: 14559927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease.
    Buysschaert B; Aydin S; Morelle J; Hermans MP; Jadoul M; Demoulin N
    Diabetes Metab; 2016 Feb; 42(1):62-4. PubMed ID: 26454353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orlistat, a new lipase inhibitor for the management of obesity.
    Heck AM; Yanovski JA; Calis KA
    Pharmacotherapy; 2000 Mar; 20(3):270-9. PubMed ID: 10730683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men.
    Pace DG; Blotner S; Guerciolini R
    J Nutr; 2001 Jun; 131(6):1694-9. PubMed ID: 11385055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of acute cholestatic hepatitis associated with Orlistat].
    Kim DH; Lee EH; Hwang JC; Jeung JH; Kim DY; Cheong JY; Cho SW; Kim YB
    Taehan Kan Hakhoe Chi; 2002 Sep; 8(3):317-20. PubMed ID: 12499790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orlistat--a novel weight loss therapy.
    Lucas KH; Kaplan-Machlis B
    Ann Pharmacother; 2001 Mar; 35(3):314-28. PubMed ID: 11261530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of orlistat in the treatment of obesity].
    Paragh G; Bajnok L
    Orv Hetil; 2005 Mar; 146(11):493-8. PubMed ID: 15813187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orlistat: current status in clinical therapeutics.
    McClendon KS; Riche DM; Uwaifo GI
    Expert Opin Drug Saf; 2009 Nov; 8(6):727-44. PubMed ID: 19998527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting.
    Schwartz SM; Bansal VP; Hale C; Rossi M; Engle JP
    Obesity (Silver Spring); 2008 Mar; 16(3):623-9. PubMed ID: 18239553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.
    Singh A; Sarkar SR; Gaber LW; Perazella MA
    Am J Kidney Dis; 2007 Jan; 49(1):153-7. PubMed ID: 17185156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interventions for the treatment of obesity in children and adolescents.
    Mead E; Atkinson G; Richter B; Metzendorf MI; Baur L; Finer N; Corpeleijn E; O'Malley C; Ells LJ
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012436. PubMed ID: 27899001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orlistat: its current status as an anti-obesity drug.
    Ballinger A; Peikin SR
    Eur J Pharmacol; 2002 Apr; 440(2-3):109-17. PubMed ID: 12007529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orlistat: a review of its use in the management of obesity.
    Hvizdos KM; Markham A
    Drugs; 1999 Oct; 58(4):743-60. PubMed ID: 10551441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.